Valneva SE (NASDAQ:VALN) Sees Large Drop in Short Interest

Valneva SE (NASDAQ:VALN - Get Free Report) was the recipient of a significant decline in short interest in January. As of January 15th, there was short interest totalling 15,900 shares, a decline of 34.6% from the December 31st total of 24,300 shares. Based on an average trading volume of 38,300 shares, the short-interest ratio is currently 0.4 days. Currently, 0.0% of the company's shares are short sold.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a "buy" rating and issued a $18.00 price target on shares of Valneva in a report on Friday.

Valneva Stock Up 10.1 %

NASDAQ VALN traded up $0.53 on Friday, reaching $5.78. The company had a trading volume of 64,274 shares, compared to its average volume of 36,012. The company's fifty day moving average is $4.35 and its 200-day moving average is $5.69. The firm has a market capitalization of $469.68 million, a price-to-earnings ratio of -44.46 and a beta of 1.93. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.25 and a current ratio of 2.78. Valneva has a 1-year low of $3.62 and a 1-year high of $9.50.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Valneva stock. AlphaCentric Advisors LLC raised its position in Valneva SE (NASDAQ:VALN - Free Report) by 33.7% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 118,000 shares of the company's stock after acquiring an additional 29,748 shares during the period. AlphaCentric Advisors LLC owned about 0.15% of Valneva worth $717,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 11.39% of the company's stock.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.